Neuromyelitis Optica Spectrum Disorder research hub
3 indexed studies · 3 currently recruiting
- recruitingPHASE3
A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
This study is looking at a new medicine called Satralizumab for children aged 2-11 with a rare condition called Neuromyelitis Optica Spectrum Disorder (NMOSD). It will primarily check how the medicine moves through the body, with a broad look at how well it works and if it's safe.
United States · Argentina · China - recruiting
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
This study looks at how well Alexion C5 inhibitor medicines work for people with a specific type of Neuromyelitis Optica Spectrum Disorder (NMOSD). It collects information over time to see how patients' health and quality of life are affected by these treatments in the real world.
United States · Argentina · Canada - not yet recruitingPHASE4
Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD
This study compares five medicines for Neuromyelitis Optica Spectrum Disorder (NMOSD) affecting the eyes and spinal cord. It aims to find which treatment best prevents relapses and has the fewest side effects for adults with NMOSD.
United States · Germany